Description: Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Home Page: belitebio.com
BLTE Technical Analysis
5820 Oberlin Drive
San Diego,
CA
92121
United States
Phone:
858-246-6240
Officers
| Name | Title |
|---|---|
| Dr. Yu-Hsin Lin M.B.A., Ph.D. | Chairman of Directors & CEO |
| Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. | CFO & Director |
| Dr. Nathan L. Mata Ph.D. | Chief Scientific Officer |
| Ms. Ching-Chen Chiu M.Sc. | VP of Clinical Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 15.4823 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-04-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 12 |